AstraZeneca PLC (AZN)vsEnbridge Inc (ENB)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
ENB
Enbridge Inc
$54.48
+0.07%
ENERGY · Cap: $116.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Enbridge Inc generates 11% more annual revenue ($65.19B vs $58.74B). AZN leads profitability with a 17.4% profit margin vs 11.5%. AZN appears more attractively valued with a PEG of 1.50. ENB earns a higher WallStSmart Score of 67/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
ENB
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+53.1%
Fair Value
$109.98
Current Price
$54.48
$55.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
2.9% earnings growth
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : ENB
The strongest argument for ENB centers on Debt/Equity, Market Cap, Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : ENB
The primary concerns for ENB are PEG Ratio, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
ENB carries more volatility with a beta of 0.86 — expect wider price swings.
ENB is growing revenue faster at 5.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ENB scores higher overall (67/100 vs 66/100). AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Enbridge Inc
ENERGY · OIL & GAS MIDSTREAM · USA
Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?